---
title: "AVTX.US (AVTX.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/AVTX.US/news.md"
symbol: "AVTX.US"
name: "AVTX.US"
parent: "https://longbridge.com/zh-CN/quote/AVTX.US.md"
datetime: "2026-03-14T00:12:23.149Z"
locales:
  - [en](https://longbridge.com/en/quote/AVTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AVTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AVTX.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/AVTX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AVTX.US/news.md)


# AVTX.US (AVTX.US) — 相关新闻

### [Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference](https://longbridge.com/zh-CN/news/278898062.md)
*2026-03-12T13:53:32.000Z*
> Avalo Therapeutics CEO Garry Neil announced that the company expects to release top-line data from its Phase 2b LOTUS tr

### [Avalon Technologies Allots 7,188 Equity Shares Under ESOP Plan](https://longbridge.com/zh-CN/news/278828424.md)
*2026-03-12T06:15:07.000Z*
> Avalon Technologies Allots 7,188 Equity Shares Under ESOP Plan

### [Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference](https://longbridge.com/zh-CN/news/277932414.md)
*2026-03-05T12:07:39.000Z*
> Avalo Therapeutics presented its strategy for AVTX-009, a monoclonal antibody targeting IL-1β, at the 46th Annual Health

### [RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX](https://longbridge.com/zh-CN/news/277184151.md)
*2026-02-27T10:48:59.000Z*
> RWA Wealth Partners LLC has reduced its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 66.9% in Q3, now holding 86,5

### [Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference](https://longbridge.com/zh-CN/news/276963645.md)
*2026-02-26T01:06:56.000Z*
> Avalo Therapeutics CEO Dr. Garry Neil highlighted the company's hidradenitis suppurativa (HS) program and the upcoming P

### [Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa](https://longbridge.com/zh-CN/news/275673577.md)
*2026-02-11T23:39:17.000Z*
> Avalo Therapeutics (NASDAQ:AVTX) is set to report phase IIb data from its LOTUS trial for AVTX-009 in hidradenitis suppu

### [Avant Technologies Changes Name to Avaí Bio](https://longbridge.com/zh-CN/news/275327673.md)
*2026-02-09T13:53:04.000Z*
### [C4 Therapeutics to Participate in Guggenheim Emerging Outlook Biotech Summit](https://longbridge.com/zh-CN/news/274807255.md)
*2026-02-04T12:00:13.000Z*
### [BIO-THERA signed a commercialization agreement for the BAT3306 (pembrolizumab) injection with Avalon Pharma](https://longbridge.com/zh-CN/news/274665036.md)
*2026-02-03T13:33:29.000Z*
> BIO-THERA has signed a licensing commercialization agreement for BAT3306 (pembrolizumab) injection with Avalon Pharma, g